Market Snapshot

BSE Sensex: 82914.5 0.50%
BSE 500: 36707.35 0.50%
BSE 200: 11617.08 0.57%
BSE 100: 26817.54 0.53%
BSE BANKEX: 68820.83 0.80%
BSE IT: 31161.97 -0.63%
Nifty 50: 25592.8 0.54%
Nifty 500: 23412.15 0.49%
Nifty 200: 14290.55 0.55%
Nifty 100: 26240.7 0.57%
Nifty Midcap 100: 59497.5 0.46%
Nifty Small 100: 17033.35 0.08%
Nifty IT: 32129.75 -0.59%
Nifty PSU Bank: 9638.75 1.40%

News:

CIE Automotive clocks PAT of R...
Paras Defence gains after buyi...
Meta Infotech rises after bagg...
Novartis India hits the roof a...
Volumes soar at Global Health ...

Concord Biotech Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap

Invest

20 Feb 2026 | 12:11 PM

1,107.80

-12.45 (-1.11%)

Add to Watchlist

This awesome feature is still in our labs.
Set Alert

This awesome feature is still in our labs.

Underperforms Index

-33.88%

Return (1Y)

Underperformed BSE Healthcare by 41.21%
More Volatile

2.58%

Standard Deviation (1Y)

Higher than BSE Healthcare by 1.69%
Inconsistent Performer

2/12

Months

underperformed BSE Healthcare
AxisDirect View

No View

52 Week High-Low

2,150

1,100

News & Announcements

Concord Biotech consolidated net profit declines 15.07% in the December 2025 quarter
8 days ago

Concord Biotech consolidated net profit declines 15.07% in the December 2025 quarter

12 - Feb - 2026 12:00 | 8 days ago

Net profit of Concord Biotech declined 15.07% to Rs 64.48 crore in the quarter ended December 2025 as against Rs 75.92 crore during the previous quarter ended December 2024. Sales rose 13.74% to Rs 277.77 crore in the quarter ended December 2025 as against Rs 244.22 crore during the previous quarter ended December 2024.

Particulars Quarter Ended
Dec. 2025 Dec. 2024 % Var.

Sales 277.77 244.22 14

OPM % 35.38 40.11 -

PBDT 108.18 114.42 -5

PBT 89.44 101.15 -12

NP 64.48 75.92 -15

Powered by Capital Market - Live News
Concord Biotech schedules board meeting
14 days ago

Concord Biotech schedules board meeting

06 - Feb - 2026 12:00 | 14 days ago

Concord Biotech will hold a meeting of the Board of Directors of the Company on 11 February 2026.
Powered by Capital Market - Live News
Concord Biotech appoints Raviraj Karia as CFO
64 days ago

Concord Biotech appoints Raviraj Karia as CFO

18 - Dec - 2025 12:00 | 64 days ago

Raviraj Karia is a chartered accountant and senior finance leader with more than 23 years of experience across pharmaceuticals, healthcare, clinical research, logistics, and private equity. His career reflects deep expertise in corporate governance, strategic finance, and business partnering, having worked closely with Boards, Promoters, CEOs, and global leadership teams.
Across leadership roles at Intas Pharmaceuticals, Sakar Healthcare, Lambda Therapeutics, Shalby Hospitals, Gati, GVFL, and Claris Lifesciences, he has delivered significant impact?managing multi billion dollar financing programs, leading India?s largest outbound pharma acquisition, facilitating marquee private equity investments, and executing global audits across Europe, the US, Latin America, and emerging markets.
Concord Biotech is a R&D driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations. It has a presence in more than 70 countries worldwide.
The company?s consolidated net profit declined 33.6% to Rs 63.58 crore on 20.3% increase in net sales to Rs 247.06 crore in Q2 FY26 over Q2 FY25.
The scrip rose 0.20% to Rs 1335 on the BSE.
Powered by Capital Market - Live News
Concord Biotech consolidated net profit declines 33.59% in the September 2025 quarter
97 days ago

Concord Biotech consolidated net profit declines 33.59% in the September 2025 quarter

15 - Nov - 2025 12:00 | 97 days ago

Net profit of Concord Biotech declined 33.59% to Rs 63.58 crore in the quarter ended September 2025 as against Rs 95.74 crore during the previous quarter ended September 2024. Sales declined 20.35% to Rs 247.06 crore in the quarter ended September 2025 as against Rs 310.18 crore during the previous quarter ended September 2024.

Particulars Quarter Ended
Sep. 2025 Sep. 2024 % Var.

Sales 247.06 310.18 -20

OPM % 35.82 43.11 -

PBDT 104.08 143.65 -28

PBT 85.68 130.34 -34

NP 63.58 95.74 -34

Powered by Capital Market - Live News

Price vs Volume

Stock Trivia

Concord Biotech Ltd is trading very close to its 52 Week Low
FII shareholding in Concord Biotech Ltd has decreased by -5.65% since past 3 Months
FII shareholding in Concord Biotech Ltd has decreased by -9.06% since past 1 Year
MF shareholding in Concord Biotech Ltd has decreased by -8.8% since past 1 Year

Peer Comparison on Risk - Return

Thanks for Liking, Please spread your love by sharing...

Particulars	Quarter Ended
	Dec. 2025	Dec. 2024	% Var.
Sales	277.77	244.22	14
OPM %	35.38	40.11	-
PBDT	108.18	114.42	-5
PBT	89.44	101.15	-12
NP	64.48	75.92	-15

Particulars	Quarter Ended
	Sep. 2025	Sep. 2024	% Var.
Sales	247.06	310.18	-20
OPM %	35.82	43.11	-
PBDT	104.08	143.65	-28
PBT	85.68	130.34	-34
NP	63.58	95.74	-34

General Notifications

My Notifications

Research Notifications

Concord Biotech Ltd Share Price – NSE / BSE Pharmaceuticals, Small Cap

1,107.80 -12.45 (-1.11%)

News & Announcements

Price vs Volume

Stock Trivia

Concord Biotech Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap

1,107.80

-12.45 (-1.11%)